08
October 2024
Past Event
Do Drug Patents Cause High Drug Prices?

Event will air on this page.

 

Inquiries: msnow@hudson.org

Do Drug Patents Cause High Drug Prices?

Past Event
Online Only
October 08, 2024
Prescription drugs are displayed at NYC Discount Pharmacy in Manhattan on July 23, 2024. (Spencer Platt via Getty Images)
Caption
Prescription drugs are displayed at NYC Discount Pharmacy in Manhattan on July 23, 2024. (Spencer Platt via Getty Images)
08
October 2024
Past Event

Event will air on this page.

 

Inquiries: msnow@hudson.org

Speakers:
Adam Mossoff
Adam Mossoff

Chair, Forum for Intellectual Property and Senior Fellow

William H. Pittman Professor of Law and Timothy J. Heinsz Professor of Law, University of Missouri School of Law
Erika Lietzan

William H. Pittman Professor of Law and Timothy J. Heinsz Professor of Law, University of Missouri School of Law

Vice President and Global Head of Intellectual Property Affairs, Novartis
Corey A. Salsberg

Vice President and Global Head of Intellectual Property Affairs, Novartis

Moderator:
hartline
Devlin Hartline

Senior Fellow

For the past decade, policy activists have argued that drug innovators artificially extend the length of their exclusive patent protections on their drugs solely to keep drug prices high. One activist organization, the Initiative for Medicines, Access, and Knowledge (I-MAK), alleges that as many as 50 patents currently protect drugs from generic competition. 

But are I-MAK’s patent numbers correct? A 2022 Hudson policy memo, “How Unreliable Data Has Infected the Policy Debate Over Drug Patents,”detailed how I-MAK’s patent numbers contradict the number of drug patents listed in the Orange Book, the Food and Drug Administration’s official database of drug patents. Academic scholars have also done rigorous empirical studies, and the United States Patent and Trademark Office (USPTO) released its own empirical study in June 2024. Neither the USPTO nor the academic studies could replicate or confirm activist organizations’ patent numbers. Yet I-MAK’s claims continue to drive legislative proposals and agency actions.

Join Hudson for an expert discussion on the state of play concerning the empirical evidence on the connection between drug patents and drug prices and whether officials are engaging in evidence-based policymaking on this pressing concern.

Related Events
30
November 2026
In-Person Event | Hudson Institute
Azerbaijan and the New American Strategy for Eurasia
Featured Speakers:
Can Kasapoğlu
Michael Doran
Ken Moriyasu
Aliyev
30
November 2026
In-Person Event | Hudson Institute
Azerbaijan and the New American Strategy for Eurasia

Join Hudson Institute for a conversation that examines Washington’s relationship with Azerbaijan.

Aliyev
Featured Speakers:
Can Kasapoğlu
Michael Doran
Ken Moriyasu
02
December 2026
In-Person Event | Invite Only
Fukuyama Was Wrong: He Missed the Challenge of Post-Democracy and Post-Liberalism
Featured Speakers:
John Fonte
Tony Abbott
Daniel McCarthy
Tom Klingenstein
Anna Wellisz
Jonathan Price
Gadi Taub
Todd Huizinga
John O'Sullivan
Mark Krikorian
Stanley Kurtz
Michael Doran
Sunrise
02
December 2026
In-Person Event | Invite Only
Fukuyama Was Wrong: He Missed the Challenge of Post-Democracy and Post-Liberalism

A conference reflecting on John Fonte’s work and the future of liberal democracy

Sunrise
Featured Speakers:
John Fonte
Tony Abbott
Daniel McCarthy
Tom Klingenstein
Anna Wellisz
Jonathan Price
Gadi Taub
Todd Huizinga
John O'Sullivan
Mark Krikorian
Stanley Kurtz
Michael Doran
02 - 03
December 2026
In-Person Event | Invitation Only
Second Annual US-China Rivalry in the Middle East Conference
Featured Speakers:
Zineb Riboua
Joel Scanlon
Can Kasapoğlu
Michael Doran
Chaim Martin
Ryan Fedasiuk
Moderators:
Ludovic Hood
Aaron MacLean
(US-China Rivalry in the Middle East logo)
02 - 03
December 2026
In-Person Event | Invitation Only
Second Annual US-China Rivalry in the Middle East Conference

Join Hudson to examine how the war with Iran, the rise of emerging technologies, and China's expanding influence are reshaping the Middle East, and what the United States must do to secure its strategic and technological leadership in the region and beyond.

(US-China Rivalry in the Middle East logo)
Featured Speakers:
Zineb Riboua
Joel Scanlon
Can Kasapoğlu
Michael Doran
Chaim Martin
Ryan Fedasiuk
Moderators:
Ludovic Hood
Aaron MacLean
08
December 2026
In-Person Event | Hudson Institute
Strengthening Japanese and Allied Critical Minerals Supply Chains: A Conversation with JOGMEC Chairman Ichiro Takahara
Featured Speakers:
William Chou
Ichiro Takahara
Kenneth R. Weinstein
Japan Chair fighting
08
December 2026
In-Person Event | Hudson Institute
Strengthening Japanese and Allied Critical Minerals Supply Chains: A Conversation with JOGMEC Chairman Ichiro Takahara

Join Hudson Institute for remarks from JOGMEC Chairman and CEO Ichiro Takahara on critical mineral resilience and allied cooperation. Japan Chair Kenneth R. Weinstein will introduce Chairman Takahara. After the chairman’s remarks, Senior Fellow William Chou will engage in a fireside discussion with him.

Japan Chair fighting
Featured Speakers:
William Chou
Ichiro Takahara
Kenneth R. Weinstein